SHR-A2102

SHR-A2102 is an investigational **Nectin-4-directed antibody-drug conjugate** developed by Hengrui Pharmaceutical for solid tumors. It comprises a fully humanized IgG1 anti-Nectin-4 monoclonal antibody, a cleavable linker, and a topoisomerase I inhibitor payload. Following binding to Nectin-4-expressing tumor cells and internalization, intracellular linker cleavage releases the cytotoxic payload, producing topoisomerase I inhibition, cell-cycle arrest, DNA damage, and tumor-cell death. The agent is being evaluated as monotherapy and in combination regimens across urothelial carcinoma, bladder cancer, non-small cell lung cancer, cervical cancer, head and neck squamous cell carcinoma, esophageal cancer, breast cancer, pancreatic cancer, and other advanced solid tumors. ([hengrui.com](https://www.hengrui.com/media/detail-746.html))

Other names

SHR A2102